Centrient Pharmaceuticals Netherlands B.V. Sustainability Profile
Centrient Pharmaceuticals Netherlands B.V., a leading player in the pharmaceutical industry, is headquartered in the Netherlands and operates across various regions globally. Founded in 2017, the company has quickly established itself as a key provider of essential medicines, particularly in the areas of antibiotics and anti-infectives. Centrient is renowned for its innovative approach to manufacturing and supplying high-quality active pharmaceutical ingredients (APIs) and finished dosage forms. Their commitment to sustainability and efficiency sets them apart in a competitive market. With a strong focus on meeting the needs of healthcare providers and patients, Centrient has achieved significant milestones, including expanding its product portfolio and enhancing its market presence. As a trusted partner in the healthcare sector, Centrient Pharmaceuticals continues to drive advancements in pharmaceutical solutions, reinforcing its position as a vital contributor to global health.
DitchCarbon Score
How does Centrient Pharmaceuticals Netherlands B.V.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Centrient Pharmaceuticals Netherlands B.V.'s score of 76 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Centrient Pharmaceuticals Netherlands B.V.'s reported carbon emissions
In 2024, Centrient Pharmaceuticals Netherlands B.V. reported total carbon emissions of approximately 697,019,000 kg CO2e. This figure includes 142,884,000 kg CO2e from Scope 1 emissions, 118,053,000 kg CO2e from Scope 2 (market-based), and 436,083,000 kg CO2e from Scope 3 emissions. The previous year, 2023, saw total emissions of about 732,956,000 kg CO2e, with Scope 1 emissions at 143,291,000 kg CO2e, Scope 2 emissions at 141,432,000 kg CO2e (market-based), and Scope 3 emissions at 448,232,000 kg CO2e. Centrient Pharmaceuticals has not set specific reduction targets or initiatives as part of their climate commitments, and there are no reported SBTi (Science Based Targets initiative) reduction targets. The emissions data is cascaded from Centrient Holding B.V., the parent company, reflecting the broader corporate family’s environmental impact. The company’s emissions profile indicates a significant reliance on Scope 3 emissions, which account for over 62% of total emissions in 2024. This highlights the importance of addressing supply chain and product lifecycle emissions in their climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 121,708,000 | 000,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 242,430,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Centrient Pharmaceuticals Netherlands B.V.'s Industry?
How Carbon Intensive is Centrient Pharmaceuticals Netherlands B.V.'s Location?
Centrient Pharmaceuticals Netherlands B.V.'s Scope 3 Categories Breakdown
Centrient Pharmaceuticals Netherlands B.V.'s Scope 3 emissions, which decreased by 3% last year and increased by approximately 22% since 2022, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 63% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 66% of Scope 3 emissions.
Top Scope 3 Categories
Centrient Pharmaceuticals Netherlands B.V.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Centrient Pharmaceuticals Netherlands B.V. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
